Drug intelligence / Profile preview

Exadipin

Development stage: Unknown
Lead developer: Dr. Auer
Modality: Small Molecules
Administration: Oral

Overview

Exadipin is a dietary supplement and food for special medical purposes (FSMP) marketed primarily in Austria for the dietary management of obesity and overweight. Developed by Dr. Auer, the formulation contains an extract of the Indian plant *Salacia reticulata*, which is rich in alpha-glucosidase inhibitors, alongside vitamin D3, zinc, and chromium. The product is designed to regulate blood sugar levels and reduce appetite by inhibiting the breakdown of carbohydrates in the digestive tract. Clinical study results indicate that Exadipin, when used in conjunction with lifestyle and fitness programs, significantly enhances weight loss and body fat reduction compared to lifestyle modifications alone.

Brand names: Exadipin
Other names: SRD

Targets

PNLIP (Pancreatic triacylglycerol lipase)Sucrase-Isomaltase

Beyond the preview

Go deeper on Exadipin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exadipin.

Explore the full profile